This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JAZZ vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. STVN: Which Stock Is the Better Value Option?
Merck's (MRK) Keytruda Head and Neck Cancer Study Fails
by Zacks Equity Research
Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.
3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock
by Zacks Equity Research
Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ultragenyx (RARE) Sells Portion of Royalty Interest for $500M
by Zacks Equity Research
Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
by Zacks Equity Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health
by Kinjel Shah
Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.
How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 28%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. STVN: Which Stock Is the Better Value Option?
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?
by Zacks Equity Research
Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
by Zacks Equity Research
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
Axsome (AXSM) Surges Following FDA Label Proposal for AXS-05
by Zacks Equity Research
Axsome (AXSM) receives proposed labeling from the FDA for its under-review depression drug candidate, AXS-05, implying a potential approval soon. Shares surge more than 50%.
Are Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Jazz (JAZZ) Down 1.5% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
by Zacks Equity Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.